The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are genetically modified cytotoxic T cells that target particular cancer-related antigens and were given clinical approval in 2017.323”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [323]
In the citing paper
“Several viral vector mediated cellular and gene-therapy products, such as Kymriah for CAR-T immunotherapy on lymphoblastic leukemia, have already gained FDA approval.[27]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [27]
Citations
Cites
Prasad, V. K., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 532
Self-citationMajhail, N. S., Mau, L., Denzen, E. M., & Arneson, T. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.133 · Cited by 143
Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 139
Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 112
FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm574154.htm · Cited by 28
Research works printed but not linked: 2
- Mitchell, D. Patients For Affordable Drugs launches campaign demanding fair pricing of new Novartis cancer drug. Patients For Affordable Drugs http://www.patientsforaffordabledrugs.org/2017/08/17/patients-for-affordable-drugs-launches-campaign-demanding-fair-pricing-of-new-cancer-drug/ (17 Aug 2017).
- Gilead Sciences, Inc. Gilead Sciences to acquire Kite Pharma for $11.9 billion. Gilead Sciences, Inc. http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion (28 Aug 2017).
Cited by
Sorted by citations
Items 201–229 of 229
Progress in the Utilization of Nanobody CAR-T Cell in Cancer Immunotherapy
Jiang, Q., Shi, W., Liu, H., Luo, H., Yang, X., & Lü, X. (2024) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2024.3906 · Cited by 1
Bioinspired drug delivery therapeutics
Faria, R., Neves, A. R., & Costa, D. R. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91816-9.00008-4 · Cited by 1
Advanced Targeting Systems for Tissue-Specific Drug Delivery
Nastasi, C. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_292 · Cited by 2
Encapsulation of single vesicles and single cells in a crosslinked microgel cage
Liu, X., Tan, S.-W., Månsson, L. K., Gunnarsson, L., Andersson, J. M., Wacklin, H. P., Crassous, J. J., & Sparr, E. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.137339 · Cited by 1
HLA-Based Immunotherapy for Cancer
James, L. M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011836 · Cited by 1
Gene-based Interventions for Cancer Immunotherapy
Cerqueira, O. L. D., Silva, G. R. O., Vieira, I. D. L., Lana, M. V. G., de Assis, N. G., Rodrigues, O. A., Valle, P. R. D., Mendonça, S. A., & Strauss, B. E. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80386 · Cited by 1
Causes, Consequences, and Control of High Cancer Drug Prices
Gyawali, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-05855-5_4 · Cited by 1
Dhar, S. K., & Das, M. (2018) · Journal of the Indian Institute of Science · doi:10.1007/s41745-018-0061-9 · Cited by 1
Bignold, L. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816920-9.00016-x · Cited by 1
Engineering Nanobody Targeting Cancer Stem Cells
Islam, M. S., Gopalan, V., & Islam, F. (2023) · Springer eBooks · doi:10.1007/978-981-99-3185-9_14 · Cited by 1
Challenge and Innovation of CAR-T Cell Therapy for Gastric Cancer: Target Antigens and Side Effects
Yu, W., Ouyang, J., Wei, M., Yu, W., Cui, X., Liang, Y., Cheng, Z., & Yan, Z. (2023) · doi:10.60125/j.conco.2023.10.02
Liu, L., Ma, C., Zhang, Z., & Chen, W. (2021) · medRxiv · doi:10.1101/2021.09.21.21263913 · Cited by 1
PhD, E. V. (2018) · doi:10.1002/9781119126843.ch5 · Cited by 1
Engineering Biomaterial Properties for T Cell Immunotherapy
Hickey, J. W. (2019)
Zan, D., Zhang, Y., Yang, H. C., Wang, K., Huang, D., & Chen, W. (2019) · IEEE/ASME International Conference on Advanced Intelligent Mechatronics · doi:10.1109/aim.2019.8868697
Gene-Editing Technologies in Adoptive T Cell Therapy for Cancer
Refolo, P., Pascali, V. L., & Spagnolo, A. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00021-2 · Cited by 1
KYMRIAH®: TERAPIA GÊNICA PARA LEUCEMIA LINFOBLÁSTICA AGUDA DE CÉLULAS B
Carvalho, T., Carraro, L., & Taketani, N. F. (2020) · Revista Ensaios Pioneiros · doi:10.24933/rep.v3i2.200
Yang, L., He, J., Liu, J., Xie, T., & Tang, Q. (2024) · Current Research in Translational Medicine · doi:10.1016/j.retram.2024.103442
Car-T cell therapy: T-immunotherapy application in blood cancer
Tan, A. J. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/48/2024pj0125
Enzing, J. J., Knies, S., Engel, J., IJzerman, M. J., Sander, B., Vreman, R. A., Boer, B., & Brouwer, W. B. F. (2022) · Figshare · doi:10.6084/m9.figshare.20761514
Manufacturing Cell-Based Products
Lorenzo, N. L., Vilariño, L. B., & Baliu‐Piqué, M. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_28
The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions
Wannaphut, C., Thirasastr, P., Livingston, J., Araujo, D. M., Conley, A. P., Keung, E. Z.-Y., Roland, C. L., & Somaiah, N. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2708435
Trap-and-drop microwell array for single-cell culture and deterministic cell pairing
Yoshida, M., Tago, S., & Kim, S. H. (2026) · Biomicrofluidics · doi:10.1063/5.0344916
Eisenmann, M., Zhu, Z., Arndt, V., & Thong, M. S. Y. (2026) · Current Oncology · doi:10.3390/curroncol33080461
Advanced Materials for Biologics Delivery to Brain Tumors
Feng, Y., Cao, Y., Kavallaris, M., Janjua, T. I., & Popat, A. (2026) · Advanced Materials · doi:10.1002/adma.74760
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases
Fan, Z., Zheng, X., Jin, C., Zhang, J., Gong, N., & Li, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02783-5
CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges
Aljabali, A. A. A., Obeid, M. A., Alqudah, A. M., Hamzat, Y., Alqudah, A., Alzoubi, L., Gammoh, O., Qnais, E. Y., Mishra, V. K., Mishra, Y., et al. (2026) · Cancers · doi:10.3390/cancers18203254
Huang, P., Wu, W., Min, Y., Zhang, Y., Tao, Y., Liu, Z., Wei, Z., & Peng, X. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00848-3
Metadata
- Authors
- Prasad, V.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Prasad, Vinay
- ORCID
- Prasad, Vinay
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-10-04
- Volume
- 15
- Issue
- 1
- Pages
- 11-12
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2761202053
- Cited by
- 229
- References
- 5
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 27 · 2023: 28 · 2022: 36 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 24 · 2017: 1
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- tisagenlecleucel, CAR T-cell therapy, FDA approval, health care costs, drug pricing, health policy, health insurance coverage, treatment toxicity, healthcare logistics
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Immunotherapy, Neoplasms, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
